Patents by Inventor Peiying Yang
Peiying Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220362275Abstract: A method of treating glioma is provided. A combination protocol as described herein includes radiotherapy, chemotherapy, and pharmacotherapy. Resection of the glioma is optionally included in the combination protocol. Pharmacotherapy is conducted with an oleandrin-containing composition. Treatment of glioblastoma is particularly contemplated.Type: ApplicationFiled: June 2, 2022Publication date: November 17, 2022Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: ROBERT A. NEWMAN, OTIS C. ADDINGTON, PEIYING YANG, CLAUDIO FESTUCCIA, JOSE R MATOS
-
Patent number: 11331291Abstract: A method of treating a triterpene-responsive condition, disease or disorder in a subject by administration of an improved triterpene-based composition is provided. An improved triterpene-based composition comprising at least two or at least three triterpenes present at a molar ratio as described herein is also provided.Type: GrantFiled: March 8, 2021Date of Patent: May 17, 2022Assignee: PHOENIX BIOTECHNOLOGY, INC.Inventors: Robert A. Newman, Otis C. Addington, Donald C. Lo, Linda S. Kaltenbach, Peiying Yang
-
Publication number: 20210267920Abstract: A method of treating a triterpene-responsive condition, disease or disorder in a subject by administration of an improved triterpene-based composition is provided. An improved triterpene-based composition comprising at least two or at least three triterpenes present at a molar ratio as described herein is also provided.Type: ApplicationFiled: March 8, 2021Publication date: September 2, 2021Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: ROBERT A. NEWMAN, OTIS C. ADDINGTON, DONALD C. LO, LINDA S. KALTENBACH, PEIYING YANG
-
Publication number: 20200281989Abstract: A method of preparing a composition for treating cancer can include collecting epidermal gel secretions of catfish, extracting the total lipid fraction from the freeze-dried epidermal gel secretions to provide a total lipid fraction including neutral lipids, glycolipids, and phospholipids. A neutral lipid fraction, a glycolipid fraction, and a phospholipid fraction can then be separated from the total lipid fraction. Each of the total lipid fraction, the neutral lipid fraction, the glycolipid fraction, and the phospholipid fraction can exhibit anti-inflammatory and/or anti-cancer activities.Type: ApplicationFiled: March 4, 2020Publication date: September 10, 2020Inventors: JASSIM M. HASSAN M. ALI, PEIYING YANG, CECIL PACE-ASCIAK
-
Patent number: 9846156Abstract: A method of treatment employing cardiac glycoside is disclosed. A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: GrantFiled: October 21, 2016Date of Patent: December 19, 2017Inventors: Otis C. Addington, Peiying Yang, Robert A. Newman
-
Patent number: 9808495Abstract: The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is fish oil or a derivative thereof. In some embodiments, the present subject matter relates to methods for modulating essential dietary fatty acid composition of lipoprotein particles or cell membranes, modulating essential fatty acid metabolism, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders.Type: GrantFiled: May 28, 2010Date of Patent: November 7, 2017Assignee: The Procter & Gamble CompanyInventors: Robert A. Newman, Peiying Yang, Paul Schulick
-
Patent number: 9795647Abstract: This disclosure relates to novel herbal compositions comprising extracts of rosemary and oregano, and methods of using the herbal compositions to modulate inflammatory potential. One or both of the extracts may be supercritical extracts. The disclosure further relates to methods of treating inflammation, rheumatoid arthritis, osteoarthritis, or combinations thereof, using the herbal compositions.Type: GrantFiled: September 12, 2014Date of Patent: October 24, 2017Assignee: The Procter & Gamble CompanyInventors: Robert A. Newman, Peiying Yang, Paul Schulick
-
Publication number: 20170067897Abstract: A method of treatment employing cardiac glycoside is disclosed. A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: ApplicationFiled: October 21, 2016Publication date: March 9, 2017Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: Otis C. ADDINGTON, Peiying YANG, Robert A. NEWMAN
-
Patent number: 9494589Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: GrantFiled: April 29, 2015Date of Patent: November 15, 2016Assignee: Phoenix Biotechnology, Inc.Inventors: Otis C. Addington, Peiying Yang, Robert A. Newman
-
Publication number: 20150316550Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: ApplicationFiled: April 29, 2015Publication date: November 5, 2015Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: Otis C. ADDINGTON, Peiying YANG, Robert A. NEWMAN
-
Patent number: 9072762Abstract: The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet.Type: GrantFiled: January 22, 2013Date of Patent: July 7, 2015Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Zhijun Liu, Peiying Yang
-
Publication number: 20150110862Abstract: Sweet gum (Liquidambar styraciflua L., family Hamamelidaceae) fruit extract was discovered to possess potent activities against multiple targets of the PI3K (phosphatidylinositide 3-kinase) pathway, especially the PI3K/Akt and mTOR pathways. At a very low concentration of 1.85 ?g/ml (IC50), sweet gun extract showed the ability of simultaneously blocking the pathways of PI3K/Akt (upstream), mTOR (mammalian target of rapamycin) (downstream), as well as its downstream protein products S6K and S6. It was also able to block 5-HETE, a lipoxygenase product that contributes to inflammation and activation of PI3K/Akt. The sweet gum fruit extract was prepared with 50% methanol (47:1; raw to extract) and concentrated to an organic fraction (210:1 raw to extract) referred as LIS-100 via reverse-phase column chromatography using a bioassay directed fractionation approach.Type: ApplicationFiled: January 6, 2015Publication date: April 23, 2015Applicants: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Board of RegentsInventors: Zhijun Liu, Peiying Yang, Robert A. Newman
-
Publication number: 20140377387Abstract: This disclosure relates to novel herbal compositions comprising extracts of rosemary and oregano, and methods of using the herbal compositions to modulate inflammatory potential. One or both of the extracts may be supercritical extracts. The disclosure further relates to methods of treating inflammation, rheumatoid arthritis, osteoarthritis, or combinations thereof, using the herbal compositions.Type: ApplicationFiled: September 12, 2014Publication date: December 25, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert A. Newman, Peiying Yang, Paul Schulick
-
Publication number: 20140206634Abstract: The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet.Type: ApplicationFiled: January 22, 2013Publication date: July 24, 2014Inventors: Zhijun Liu, Peiying Yang
-
Publication number: 20130324485Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: ApplicationFiled: January 30, 2013Publication date: December 5, 2013Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: Otis C. ADDINGTON, Peiying YANG, Robert A. NEWMAN
-
Patent number: 8367363Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: GrantFiled: May 4, 2010Date of Patent: February 5, 2013Assignee: Phoenix Biotechnology, Inc.Inventors: Otis Crandell Addington, Robert A. Newman, Peiying Yang
-
Publication number: 20110189220Abstract: The present subject matter relates to a novel mushroom composition and methods for making and using the same. In one aspect, the subject matter involves a composition comprising a combination of mushrooms or components derived from mushrooms selected from the group consisting of Reishi Ganoderma lucidum, Reishi Ganoderma lucidum, Cordyceps sinensis, Maitake Grifola frondosa, Shiitake Lentinula edodes, Poria cocos, Lion's Mane Hericium erinaceus, Mesima Phellinus linteus, Turkey Tail Coriolus Tramentes versicolor, Chaga Inonotus obliquus, and Chaga Inonotus obliquus. In some embodiments, the present subject matter relates to methods for modulating immune function, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders. In one embodiment the composition provides a balancing of anti-inflammatory and pro-inflammatory function in an animal, including in humans.Type: ApplicationFiled: January 28, 2011Publication date: August 4, 2011Applicants: NEW CHAPTER INC., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Peiying YANG, Robert NEWMAN, Paul SCHULICK
-
Publication number: 20110039796Abstract: The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet.Type: ApplicationFiled: April 16, 2010Publication date: February 17, 2011Inventors: Zhijun Liu, Peiying Yang
-
Publication number: 20110008457Abstract: The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is fish oil or a derivative thereof. In some embodiments, the present subject matter relates to methods for modulating essential dietary fatty acid composition of lipoprotein particles or cell membranes, modulating essential fatty acid metabolism, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders.Type: ApplicationFiled: May 28, 2010Publication date: January 13, 2011Applicants: NEW CHAPTER INC., BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Robert A. NEWMAN, Peiying YANG, Paul SCHULICK
-
Publication number: 20100317541Abstract: A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the ? subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.Type: ApplicationFiled: May 4, 2010Publication date: December 16, 2010Applicant: PHOENIX BIOTECHNOLOGY, INC.Inventors: Otis Crandell ADDINGTON, Robert A. NEWMAN, Peiying YANG